AI assistant
AstraZeneca PLC — Board/Management Information 2018
Jun 26, 2018
5229_rns_2018-06-26_29dff50d-7e33-4b26-ab08-df8a24e27bd7.html
Board/Management Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 5247S
AstraZeneca PLC
26 June 2018
26 June 2018 07:00 BST
BOARD COMMITTEE CHANGES
AstraZeneca PLC (the Company) today announced the following Board Committee changes.
Science Committee:
With effect from 1 July 2018, Nazneen Rahman will become permanent Chairman of the Science Committee. Professor Rahman joined the Science Committee on her appointment as a Director on 1 June 2017 and has been interim Chairman of the Committee since November 2017.
Audit Committee:
With effect from 30 June 2018, Shriti Vadera will step down as a member of the Audit Committee. As previously announced, Shriti Vadera has informed the Board that she will retire as a Director by 31 December 2018. With effect from 1 November 2018, Deborah DiSanzo will become a member of the Audit Committee.
Remuneration Committee:
With effect from 1 July 2018, Sheri McCoy will become a member of the Remuneration Committee.
Nomination and Governance Committee:
With effect from 1 July 2018, Nazneen Rahman will become a member of the Nomination and Governance Committee.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
| Media Relations | ||
| Karen Birmingham | UK/Global | +44 203 749 5634 |
| Rob Skelding | UK/Global | +44 203 749 5821 |
| Matt Kent | UK/Global | +44 203 749 5906 |
| Gonzalo Viña | UK/Global | +44 203 749 5916 |
| Jacob Lund | Sweden | +46 8 553 260 20 |
| Michele Meixell | US | +1 302 885 2677 |
| Investor Relations | ||
| Thomas Kudsk Larsen | +44 203 749 5712 | |
| Josie Afolabi | +44 203 749 5631 | |
| Craig Marks | Finance; Fixed Income; M&A | +44 7881 615 764 |
| Henry Wheeler | Oncology | +44 203 749 5797 |
| Mitchell Chan | Oncology; Other | +1 240 477 3771 |
| Christer Gruvris | Brilinta; Diabetes | +44 203 749 5711 |
| Nick Stone | Respiratory; Renal | +44 203 749 5716 |
| Jennifer Kretzmann | Retail Investors | +44 203 749 5824 |
| US toll-free | +1 866 381 7277 | |
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
BOAEAXKSADXPEFF